Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings

Hemostemix closes $480,000 financing

By The Northwire Desk — AI Analysis Dec 31, 2025 · 18:13 HEM · 0.09 Hemostemix Inc
HEM · Price

Executive Summary

  • Hemostemix Inc. has closed a non-brokered private placement raising aggregate gross proceeds of $480,000.
  • The company issued 4,000,000 common shares at a price of $0.12 per share.
  • Proceeds are designated for general working capital, specifically to advance regulatory, clinical, and commercialization initiatives for its autologous angiogenic cell therapy platform, ACP-01 (VesCell).

Key Details

  • Transaction Type: Non-brokered private placement.
  • Gross Proceeds: $480,000.
  • Share Price: $0.12 per common share.
  • Shares Issued: 4,000,000 common shares.
  • Use of Proceeds: General working capital, including advancing regulatory, clinical, and commercialization initiatives for ACP-01 (VesCell).
  • Regulatory Status: Subject to final acceptance by the TSX Venture Exchange (TSX-V).
  • Restrictions: All securities are subject to a statutory hold period in accordance with applicable securities laws and TSX-V policies.

Notable Quotes

  • No direct quotes from management were included in the provided text.
Read the original news release →

More from Hemostemix Inc

Jun 26, 2026 · 08:48

Pre-revenue stem cell therapy developer advancing ACP-01 across ischemic indications while navigating severe liquidity constraints and ongoing dilutive financings.

Financings Jun 17, 2026 · 17:23

Micro-cap Biotech Cuts Financing Price in Half Amid Restatement and Going Concern Warnings

Financings Feb 03, 2026 · 08:56

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Management Jan 16, 2026 · 16:06

Hemostemix gets FDA support for basket protocol

Regulatory Jan 16, 2026 · 12:27

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Regulatory Dec 31, 2025 · 14:39

Hemostemix Closes $480,000 Private Placement at $0.12 per Share

Financings